Minimal change glomerular disease associated with solid neoplasms: a systematic review.
Cozzo D, Orlando F, Bruno M, Ogna A, Forni Ogna V.
J Nephrol. 2025 Mar;38(2):343-352. doi: 10.1007/s40620-024-02084-6. Epub 2024 Oct 1.
Paraneoplastic glomerulopathies.
Norris SH.
Semin Nephrol. 1993 May;13(3):258-72.
Onco-nephrology: glomerular diseases with cancer.
Cambier JF, Ronco P.
Clin J Am Soc Nephrol. 2012 Oct;7(10):1701-12. doi: 10.2215/CJN.03770412. Epub 2012 Aug 16.
Serum levels of tumor associated trypsin inhibitor (TATI) and glomerular filtration rate.
Tramonti G, Ferdeghini M, Donadio C, Annichiarico C, Norpoth M, Bianchi R, Bianchi C.
Ren Fail. 1998 Mar;20(2):295-302. doi: 10.3109/08860229809045114.
Glomerular injury in patients with neoplasia.
Kaplan BS, Klassen J, Gault MH.
Annu Rev Med. 1976;27:117-25. doi: 10.1146/annurev.me.27.020176.001001.
Wilms tumor and the WT1 gene.
Lee SB, Haber DA.
Exp Cell Res. 2001 Mar 10;264(1):74-99. doi: 10.1006/excr.2000.5131.
Wilms' tumor and glomerular disease. Occurrence with features of membranoproliferative glomerulonephritis and secondary focal, segmental glomerulosclerosis.
Thorner P, McGraw M, Weitzman S, Balfe JW, Klein M, Baumal R.
Arch Pathol Lab Med. 1984 Feb;108(2):141-6.
Tumor marker elevations in chronic kidney disease: a retrospective study.
You L, Xu Z, Liu Q, Jin G, Wang C.
PeerJ. 2025 Apr 3;13:e19240. doi: 10.7717/peerj.19240. eCollection 2025.
[Glomerulonephritis in neoplastic disease].
Mazanowska O, Klinger M.
Pol Merkur Lekarski. 2005 Aug;19(110):211-4.
Membranous nephropathy-one morphologic pattern with different diseases.
Hoxha E, von Haxthausen F, Wiech T, Stahl RAK.
Pflugers Arch. 2017 Aug;469(7-8):989-996. doi: 10.1007/s00424-017-2000-4. Epub 2017 May 29.
